Healthy Skepticism Library item: 6648

Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.

Publication type: Journal Article

Lexchin J.
Re: the promotion of Ponstan (mefenamic acid)
1996 Jan;

Abstract:

MaLAM is complaining to the IFPMA about the marketing of Ponstan (mefenamic acid) in Pakistan by Parke-Davis.

Keywords:
*analysis/Pakistan/developing countries/Ponstan/Parke-Davis/ antipyretics/ children/ Code of Pharmaceutical Marketing Practices (IFPMA)/quality of information/safety & risk information/IFPMA/International Federation of Pharmaceutical Manufacturers Associations/ MaLAM/ Medical Lobby for Appropriate Marketing/ETHICAL ISSUES IN PROMOTION: COMPANY STANDARDS/EVALUATION OF PROMOTION: DRUG SAFETY/PROMOTION AND HEALTH NEEDS: PROMOTION IN DEVELOPING COUNTRIES/REGULATION, CODES, GUIDELINES: INDUSTRY SELF-REGULATION